Attention Deficit Hyperactivity Disorder (ADHD) is the most common developmental disorder in school-age children. Often undetected or misunderstood, it can have a huge impact on children, their families and the wider community. Questions of whether ADHD remits in adulthood, whether it is caused by genes or environment, and how it should be treated, remain the subjects of widespread discussion and some controversy.
Until now, ADHD has been measured by the presentation of behavioural patterns and characteristics, using questionnaires and often highly subjective information provided by close observers of the child’s behaviour. When a diagnosis is made, the use of pharmaceutical interventions is often resisted by patients, parents and caregivers, who may have concerns about the reaction to such drugs. Negative physiological aspects and the stigma of taking medication to manage behaviour can sometimes lead to poor compliance.
Mentis Cura aims to launch and ADHD diagnostic aid in 2021. The tool is positioned to help clinicians – and to a certain extent the patient and parent/caregiver – to understand features of ADHD evident in an EEG recording. In doing so, it is an objective marker that enhances the accuracy of ADHD diagnosis in young people (10-16 years), thereby providing added reassurance for everyone involved.